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treatment in each patient with a rare 
EGFR mutation is of utmost impor-
tance to identify every patient who can 
benefit from this therapeutic modality.
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of formalin-fixed paraffin embedded 
tumor tissues or cytological samples, 
and the majority of cases were analyzed 
from bronchoscopic biopsy specimens, 
where the amount of DNA available for 
analysis was limited. Indeed, throughout 
the world, the overwhelming majority of 
EGFR molecular testing is performed on 
formalin-fixed surgical tumor specimens 
or biopsies, or even on cytological prep-
arations. We fully agree with Domingues 
et al. that the EGFR mutation analysis 
should be very carefully performed and 
interpreted, especially when rare or novel 
mutations are found. Therefore, we not 
only pointed out the possible clinical rel-
evance of rare EGFR mutations but also 
stated clearly in the interpretation of our 
results that our data needs to be validated 
in additional studies. However, it is now 
evident that certain rare mutations are 
sensitizing to anti-EGFR therapy and 
that these patients need to be identified 
and treated accordingly.1,2
It is important to discuss the pos-
sibility of formalin-fixation-related 
polymerase chain reaction artifacts 
in our study. First, the majority of the 
nonsynonymous rare EGFR mutations 
identified in our cohort have already 
been described in the COSMIC data-
base. Among the 20 previously not 
published rare EGFR mutations, there 
were three microdeletions and five 
point mutations which were not C->T 
or G->A transitions that often appear as 
formalin induced artifacts. Of note, five 
patients with novel rare EGFR mutations 
responded to therapy and had a survival 
benefit which would not be expected in 
the case of artifact mutations (i.e., in 
wild-type EGFR patients). Nevertheless, 
we hope that because an increasing 
number of EGFR  mutation analyses 
are being performed on non-formalin-
fixed specimens the spectra of validated 
somatic EGFR  mutations will eventually 
be established. Novel approaches—for 
instance using circulating tumor DNA in 
“liquid biopsy”—may overcome some 
of the limitations in the future.3
In summary, on the one hand, the 
harmonization of tissue processing and 
molecular pathological methods can 
further improve the reliability of EGFR 
mutational tests. On the other hand—as 
we concluded in our study—reporting 
the clinical response to EGFR-TKI 
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To the Editor:
The Chinese Thoracic Oncology 
Group has recently reported final over-
all survival (OS) results of a phase III 
study examining the effectiveness of 
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maintenance gefitinib in patients with 
advanced non–small-cell lung cancer 
without disease progression after first-
line chemotherapy. In terms of the results, 
maintenance treatment with gefitinib 
significantly improved OS compared 
with placebo in epidermal growth fac-
tor receptor (EGFR) mutation-positive 
patients, whereas there was no survival 
difference between gefitinib and pla-
cebo in mutation-negative or unknown 
patients.1 Should we use gefitinib as 
maintenance therapy for mutation-
positive patients once disease control is 
achieved after first-line chemotherapy?
In the first place, EGFR muta-
tion analysis was conducted in only 30 
patients (10%) in the study. In addi-
tion, 47% of the patients assigned 
to the placebo group never received 
any EGFR tyrosine kinase inhibitors 
(TKIs) as their post-study treatment, 
which may have affected the results. 
The preceding SATURN study failed to 
demonstrate an OS benefit in mutation-
positive patients, which may have been 
due to extensively high cross-over in 
the placebo group.2 Considering that 
EGFR-TKI is similarly effective in the 
second-line setting3 and that it some-
times causes fatal adverse events, such 
as interstitial lung disease,4 we should 
be cautious over the use of EGFR-TKI 
as maintenance treatment after chemo-
therapy in mutation-positive patients.
On the other hand, subgroup anal-
yses of the SATURN study suggested 
that maintenance EGFR-TKI may 
lead to significant OS improvement in 
mutation-positive patients who achieve 
stable disease after first-line chemo-
therapy (hazard ratio [HR]: 0.48; 95% 
confidence interval [CI]: 0.14–1.62).2 
Considering that patients with a smaller 
decrease in target lesions are also less 
likely to receive subsequent treatment,5 
an earlier start of EGFR-TKI may be 
beneficial in patients with a mutation-
positive status and stable disease fol-
lowing first-line chemotherapy.
Recently, mutation analyses 
including EGFR have routinely been 
performed before first-line treatment in 
patients with advanced non–small-cell 
lung cancer in many cases, and EGFR-
TKI is usually selected as a first-line 
treatment for EGFR mutation-positive 
patients. In such patients, continuation 
EGFR-TKI beyond disease progres-
sion may prolong OS6, while it may 
lead to decrease the opportunity to 
receive effective chemotherapy and 
compromise the survival as a result. 
Continuation of gefitinib in combina-
tion with chemotherapy did not improve 
progression-free survival and rather 
compromised OS compared with che-
motherapy alone.7 Optimal timing to 
change treatments from EGFR-TKI to 
chemotherapy is another and more cru-
cial issue to be resolved.
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Regarding the first issue, 
INFORM study results did not sup-
port the routine use of epidermal 
growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs) for mainte-
nance treatment as a standard of care 
in all patients with advanced non–
small-cell lung cancer (NSCLC). 
We agree with Dr. Kim that the sub-
groups with mutation-positive and 
mutation-negative patients in the 
INFORM study were small (n = 79). 
Moreover, the crossover rate in the 
INFORM study was lower than that 
in the  phase 3,  placebo-controlled 
Sequential Tarceva in Unresectable 
NSCLC (SATURN) study (67% ver-
sus 53%).1 This may explain the dif-
ference in OS result between our 
INFORM study and the SATURN 
study in mutation-positive patients. On 
the other hand, we do not agree with 
Dr. Kim’s argument about the overuse 
of maintenance treatment for patients 
with EGFR mutation. First, previ-
ous first-line studies had proved that 
the first-line use of EGFR-TKIs in 
 mutation-positive patients was asso-
ciated with better progression-free 
survival and favorable toxicity profile 
when compared with first-line chemo-
therapy.2 However, none of these first-
line studies show OS benefit, and use of 
EGFR-TKIs still became the standard 
of care for first-line treatment of these 
mutation-positive patients. Second, 
current data indicate that the risk of 
interstitial lung disease associated 
